» Articles » PMID: 15305188

A Note on Competing Risks in Survival Data Analysis

Overview
Journal Br J Cancer
Specialty Oncology
Date 2004 Aug 12
PMID 15305188
Citations 267
Authors
Affiliations
Soon will be listed here.
Abstract

Survival analysis encompasses investigation of time to event data. In most clinical studies, estimating the cumulative incidence function (or the probability of experiencing an event by a given time) is of primary interest. When the data consist of patients who experience an event and censored individuals, a nonparametric estimate of the cumulative incidence can be obtained using the Kaplan-Meier method. Under this approach, the censoring mechanism is assumed to be noninformative. In other words, the survival time of an individual (or the time at which a subject experiences an event) is assumed to be independent of a mechanism that would cause the patient to be censored. Often times, a patient may experience an event other than the one of interest which alters the probability of experiencing the event of interest. Such events are known as competing risk events. In this setting, it would often be of interest to calculate the cumulative incidence of a specific event of interest. Any subject who does not experience the event of interest can be treated as censored. However, a patient experiencing a competing risk event is censored in an informative manner. Hence, the Kaplan-Meier estimation procedure may not be directly applicable. The cumulative incidence function for an event of interest must be calculated by appropriately accounting for the presence of competing risk events. In this paper, we illustrate nonparametric estimation of the cumulative incidence function for an event of interest in the presence of competing risk events using two published data sets. We compare the resulting estimates with those obtained using the Kaplan-Meier approach to demonstrate the importance of appropriately estimating the cumulative incidence of an event of interest in the presence of competing risk events.

Citing Articles

Persistent advanced HIV disease in rural KwaZulu-Natal, South Africa: Trends, characteristics, and the urgent need for targeted interventions.

Kitenge M, Fatti G, Eshun-Wilson I, Nyasulu P PLoS One. 2025; 20(2):e0317674.

PMID: 39965033 PMC: 11835316. DOI: 10.1371/journal.pone.0317674.


Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.

Ergas I, Cheng R, Roh J, Kresovich J, Iribarren C, Nguyen-Huynh M Breast Cancer Res Treat. 2025; .

PMID: 39890673 DOI: 10.1007/s10549-025-07629-2.


Post-acute sequelae of COVID-19 in cancer patients: Two cohorts in UK and Hong Kong.

Wan E, Lee S, Zhou J, Yan V, Lai F, Chui C Cancer Med. 2024; 13(23):e70134.

PMID: 39644256 PMC: 11624603. DOI: 10.1002/cam4.70134.


Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study.

Tolley E, Tolley Dr E, Nielsen T, Hersby D, Ostergaard S, Rasmussen M Blood Adv. 2024; 9(4):893-905.

PMID: 39571170 PMC: 11876834. DOI: 10.1182/bloodadvances.2024014404.


Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models.

Dudasova J, Valenta Z, Sachs J NPJ Vaccines. 2024; 9(1):214.

PMID: 39528514 PMC: 11554669. DOI: 10.1038/s41541-024-00937-6.


References
1.
Gail M . A review and critique of some models used in competing risk analysis. Biometrics. 1975; 31(1):209-22. View

2.
Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A . Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999; 91(24):2112-7. DOI: 10.1093/jnci/91.24.2112. View

3.
Tai B, Machin D, White I, Gebski V . Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Stat Med. 2001; 20(5):661-84. DOI: 10.1002/sim.711. View

4.
Kutler D, Singh B, Satagopan J, Batish S, Berwick M, Giampietro P . A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2002; 101(4):1249-56. DOI: 10.1182/blood-2002-07-2170. View

5.
Pepe M, Mori M . Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?. Stat Med. 1993; 12(8):737-51. DOI: 10.1002/sim.4780120803. View